{"entity":{"id":"nct07216443","kind":"trial","name":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","aka":[],"tldr":"A phase 2 trial of Orca-T in myelodysplastic syndromes / neoplasms, run by Orca Biosystems, Inc., now recruiting.","summary":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 2 interventional study registered as NCT07216443 by Orca Biosystems, Inc., with 80 participants planned, started 2025-12-09 and due to reach its primary completion in 2027-11. Interventions recorded: Orca-T.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07216443","url":"https://clinicaltrials.gov/study/NCT07216443"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds","mds-higher-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["orca-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07216443","phase":"2","setting":"A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","sponsor":"Orca Biosystems, Inc.","started":"2025-12-09","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07216443/","neighbours":{"cancer":[{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"company":[{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/"}]}}